Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03873948
Other study ID # 12-16
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 6, 2014
Est. completion date March 1, 2019

Study information

Verified date October 2019
Source University of Messina
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Asymmetric dimethylarginine (ADMA) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and coronary heart disease (CHD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum ADMA levels.


Description:

The aim of this study was to evaluate a possible association between both saliva and serum ADMA levels in patients with CP and with CHD and if the serum ADMA levels are mediated by serum CRP.


Recruitment information / eligibility

Status Completed
Enrollment 141
Est. completion date March 1, 2019
Est. primary completion date August 8, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 75 Years
Eligibility Inclusion Criteria:

- Presence of at least 16 teeth

- CP with a minimum of 40% of sites with a clinical attachment level (CAL) =2mm and probing depth (PD) =4mm;

- Presence of at least =2 mm of crestal alveolar bone loss verified on digital periapical radiographs

- Presence of =40% sites with bleeding on probing (BOP)

Exclusion Criteria:

- Intake of contraceptives

- Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study

- Status of pregnancy or lactation

- Previous history of excessive drinking

- Allergy to local anaesthetic

- Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Study Design


Intervention

Other:
Evaluation of arginine serum level
correlation of serum arginine level with periodontal and cardiovascular disease

Locations

Country Name City State
Italy University of Messina Messina

Sponsors (1)

Lead Sponsor Collaborator
University of Messina

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Attachment level 1 year
See also
  Status Clinical Trial Phase
Completed NCT00546052 - A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331) Phase 3
Completed NCT02650674 - Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products N/A
Completed NCT00707746 - Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects Phase 2
Completed NCT02573103 - Air Pollution and Cardiovascular Disease
Not yet recruiting NCT06051461 - Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular Communication N/A
Not yet recruiting NCT05013112 - Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) N/A
Enrolling by invitation NCT04654000 - Rheopheresis as Adjuvant Treatment of Calciphylaxis N/A
Completed NCT01337141 - A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients N/A
Completed NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Phase 2
Recruiting NCT03882580 - Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Active, not recruiting NCT01911091 - Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus) N/A
Completed NCT00607373 - Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Phase 3
Completed NCT00362180 - Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Phase 2
Completed NCT01738061 - A Multidimensional Lifestyle Intervention to Reduce the Risk of Metabolic Disorders in Older Workers in Taiwan N/A
Completed NCT02059993 - The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease N/A
Completed NCT06129578 - Plant Protein Supplementation Within a Healthy Lifestyle Modulates Plasma Circulating Amino Acids and Improves the Health Status of Overweight Individuals N/A
Completed NCT06331572 - Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
Completed NCT05255718 - Impact of Aronia Berry Consumption on Inflammation, Metabolites, and the Gut Microbiome N/A
Completed NCT00694109 - An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia Phase 3